Recardio Secures $3,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f6660944-f184-4c2c-9d8a-703e78e7eb38 - Date
11/16/2015 - Company Name
Recardio - Mailing Address
1 Market Street Spear Tower 36th Floor San Francisco, CA 94105 USA - Company Description
RECARDIO (REgenerative CARDIOvascular Therapy) is an Austrian based life science company founded in 2011. It is focusing on drug based regenerative therapeutic modalities for the treatment of cardiovascular diseases. - Website
http://www.recardio.eu - Transaction Type
Venture Equity - Transaction Amount
$3,000,000 - Transaction Round
Series A - Proceeds Purposes
The proceeds will be used to advance a Phase 2 clinical trial for Recardio’s lead therapeutic candidate, Dutogliptin, which is being developed for the treatment of acute myocardial infarction (AMI), commonly known as heart attack. - M&A Terms
- Venture Investor
Undisclosed
